FDA Peptide Compounding Policy: What Changes

On October 14, the White House budget office logged a new FDA peptide plan for review, and Reuters reported it the next day (Reuters). If this one goes ahead, the FDA could choose not to act against licensed pharmacies that make some popular peptides with a prescription. That would be a big shift after three years of these peptides being off-limits to pharmacies. But the plan isn't out yet, and even if it's issued, it wouldn't change the law (Holland & Knight).

Who This Helps

This is for anyone who's curious about peptides like BPC-157 and has been waiting for a way to get them through a licensed pharmacy. It's also for anyone who has seen "research use only" vials online and wondered if this news makes them okay to buy. (It doesn't. Lawyers don't expect the plan to cover them and they already work outside normal legal jurisdiction.)

What the FDA actually did

The policy's full name is the "Interim Access Policy for Compounding Using Certain Peptides." The White House budget office logged it on October 14 (OMB). The filing itself doesn't give details of what the policy says (Reuters). Lawyers who track this note that it isn't a formal rule, and details haven't come out yet (Holland & Knight).

Two people who know the plan told the AP news service it would let pharmacies make some popular ones, including BPC-157, for a time. They said pharmacies making them wouldn't be targeted (AP). That means the FDA would choose not to act against licensed pharmacies that follow its terms. That wouldn't make them approved drugs, and the FDA could change a plan like this later without a new rule (Holland & Knight).

How we got here

2023: the FDA put more than a dozen peptides on a list of ingredients it saw as risky. In practice, that put them off-limits for licensed pharmacies to compound (FDA Law Blog).
April 2026: the FDA took 12 peptides off that list (Holland & Knight). Lawyers said that alone didn't make them legal for pharmacies to make (Goodwin).
July 2026: a panel that advises the FDA backed six of the seven peptides it looked at, including BPC-157, KPV and TB-500. Each of those three passed 8 to 6, with one abstention (Holland & Knight). FDA staff had advised against all seven.
October 2026: the new plan went to the White House for review.

We covered the July vote and what a legal path looks like in our guide to peptides at telehealth checkouts.

Find a provider in your state

Answer a few questions and see live pricing from the providers that ship where you live.

Get started

What it means for you right now

Today, nothing has changed. As of October 20, the OMB listing still shows the plan under review. NPR reported in August that it's still illegal for US pharmacies to make the peptides the panel reviewed (NPR). Even if the plan is issued, the law stays the same. The FDA would be choosing not to act against pharmacies that meet its terms, and lawyers note it could reverse that at any time.

If the plan is issued, you'd most likely get them through a licensed pharmacy with a prescription (NPR), similar to how compounded GLP-1s work. Even then it won't be instant. The head of a compounding pharmacy trade group told NPR it could take two to nine months, depending on the peptide (NPR). State pharmacy boards would still apply their own rules, since a plan like this doesn't bind them (Holland & Knight).

What it won't cover: the gray market. Lawyers don't expect it to apply to "research use only" sellers or supplements (Holland & Knight). The FDA sent five warning letters to online peptide sellers on August 24 (Holland & Knight). Weight loss drugs sold as research peptides, like the retatrutide we covered recently, are a separate problem (GLP Winner).

Under federal rules, 503A compounding pharmacies must buy raw ingredients from a maker registered with the FDA, with a certificate of analysis (a lab report) for that batch (FDA). On a gray-market seller's website, the seller usually picks the lab and decides which results to post (GLP Winner).

What people are saying

Supporters see this as a way to move people out of an unsafe market they're already in. The head of the federal health department has said more people are turning to gray-market peptides, and that pharmacies should be allowed to sell them (AP). The head of a compounding pharmacy trade group that wants the change was blunt with NPR in March: "The black market and the gray market are running amok" (NPR).

Critics worry the science hasn't caught up. Most of the research on these peptides comes from animal studies (AP). Two patient safety groups, ECRI and ISMP, warned that repeat shots can set off immune reactions (Becker's). One member of the July panel who voted no, Dr. Brian Lee of USC, said the endorsement "can be potentially harmful" (NPR). NPR also reported that most of the panel's new members had ties to the peptide industry. The health department said they'd all been through its usual ethics checks (NPR).

Supporters argue a pharmacy route is safer than the gray market. Critics answer that a pharmacy label doesn't fill the gap in human studies.

What's still unknown

Which peptides it covers, since the text isn't public yet.
Which kinds of pharmacies it applies to. Lawyers at one firm are asking if it covers only local compounding pharmacies (503A) or also outsourcing facilities (503B) (Buchanan Ingersoll). Holland & Knight expects it won't cover 503B outsourcing facilities. Our 503A vs 503B guide explains the difference.
The terms they'll have to meet, such as where ingredients come from and basic quality standards (Frier Levitt), and reporting side effects (Holland & Knight).
Whether anyone sues, since some drug company groups argue the FDA can't allow this through a policy alone (Holland & Knight).

Final Takeaway

The FDA's new plan could open a pharmacy route for some popular peptides. But it hasn't been issued, and even if it is, it would pause enforcement and leave the law as it is. If it goes ahead, expect a prescription, a licensed pharmacy and a wait for supply. Until then, skip the "research use only" vials, and if you're curious, talk with a clinician and ask where any product would come from.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

Frequently Asked Questions

Is BPC-157 legal now?

Not under current law. The White House budget office logged an FDA policy for review on October 14, 2026, and reports say it's meant to cover BPC-157, but it hasn't been issued. Even if it is, the FDA would only be choosing not to act against pharmacies that meet its terms; the law wouldn't change.

Will I need a prescription for compounded peptides?

Very likely. Earlier reporting on peptide access said these drugs would need a prescription, and that's how pharmacy compounding works for other drugs. The plan's text isn't public yet, so its exact terms aren't known.

Does this make research peptides sold online safe?

No. The policy isn't expected to cover "research use only" sellers, and the FDA has been sending warning letters to sellers who market these vials for people to use.